TELEPAQUE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TELEPAQUE is an oral tablet diagnostic agent approved in 1951 by GE HealthCare, now in late-stage lifecycle approaching loss of exclusivity. The exact indication and mechanism of action are not specified in available data, but the oral route and tablet formulation suggest a radiographic or imaging contrast agent. This legacy product represents a foundational diagnostic tool from the mid-20th century pharmaceutical era.
LOE Approaching
A mature, legacy diagnostic product with approaching loss of exclusivity; expect minimal team expansion and focus on cost management and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Positions on TELEPAQUE teams are primarily operational and defensive, focusing on regulatory compliance, cost management, and profitable wind-down rather than growth or innovation. This product is suitable for professionals seeking stable, specialized roles in legacy asset management, with limited advancement potential but predictable responsibilities.
Regulatory Affairs Specialist
Worked on TELEPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.